{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-23-000072","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.063091+00:00","generated_at":"2026-06-08T16:09:42.820346+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Entrada Therapeutics Q3 net income $35.5M; initiates Phase 1 for DMD candidate ENTR-601-44","bullets":["Net income of $35.5M in Q3 2023 vs net loss of $(25.1M) in Q3 2022, driven by $43.7M collaboration revenue.","Cash, cash equivalents and securities of $353.6M as of Sep 30, 2023; runway expected through 2025.","Dosed first participant in Phase 1 trial of ENTR-601-44 for Duchenne muscular dystrophy; data expected H2 2024.","Selected third Duchenne candidate ENTR-601-50 with IND/CTA planned for 2025; preclinical data expected H1 2024.","Achieved Vertex milestone triggering $17.5M payment; entered license for ENTR-501 with Pierrepont Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-23-000072","json":"https://secwatch.observer/filing/0001689375-23-000072.json","markdown":"https://secwatch.observer/filing/0001689375-23-000072.md","text":"https://secwatch.observer/filing/0001689375-23-000072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000072/0001689375-23-000072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000072/trda-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T16:09:42.820346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"36060d38a240ddd8a1a973224b230a9e53649420","claim":"Entrada Therapeutics, Inc. reported third quarter ending September 30, 2023 results: revenue $43.7 million, net income $35.5 million.","evidence_excerpt":"milestones, will be sufficient to fund the Company's operating expenses and capital expenditure requirements through 2025. Collaboration Revenue: Collaboration revenue was $43.7 million for the third quarter of 2023. There was no collaboration revenue in the third quarter of 2022. Research & Development (R&D) Expenses: R&D expenses were $22.2 million for the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000072/0001689375-23-000072-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ending September 30, 2023"},{"label":"Revenue","value":"$43.7 million"},{"label":"Net income","value":"$35.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}